The detection of novelty relies on dopaminergic signaling: evidence from apomorphine's impact on the novelty N2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23840482.
- Also identified by DOI 10.1371/journal.pone.0066469 and PMC identifier 3688774.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Despite much research, it remains unclear if dopamine is directly involved in novelty detection or plays a role in orchestrating the subsequent cognitive response. This ambiguity stems in part from a reliance on experimental designs where novelty is manipulated and dopaminergic activity is subsequently observed. Here we adopt the alternative approach: we manipulate dopamine activity using apomorphine (D1/D2 agonist) and measure the change in neurological indices of novelty processing. In separate drug and placebo sessions, participants completed a von Restorff task. Apomorphine speeded and potentiated the novelty-elicited N2, an Event-Related Potential (ERP) component thought to index early aspects of novelty detection, and caused novel-font words to be better recalled. Apomorphine also decreased the amplitude of the novelty-P3a. An increase in D1/D2 receptor activation thus appears to potentiate neural sensitivity to novel stimuli, causing this content to be better encoded.
Medical subject headings
- Apomorphine
- Dopamine Agonists
- Dopaminergic Neurons
- Event-Related Potentials, P300
- Evoked Potentials, Visual